|
1
|
Quan JL, Feng Y, Chen J and Fu DL: Current
status and progress of pancreatic cancer in China. World J
Gastroenterol. 21:7988–8003. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen WQ, Li H, Sun KX, Zheng RS, Zhang SW,
Zeng HM, Zou XN, Gu XY and He J: Report of cancer incidence and
mortality in different areas of China, 2014. Zhonghua Zhong Liu Za
Zhi. 40:5–13. 2018.(In Chinese). PubMed/NCBI
|
|
3
|
Kongkam P, Benjasupattananun P, Taytawat
P, Navicharoen P, Sriuranpong V, Vajragupta L, Klaikaew N, Ridtitid
W, Treeprasertsuk S, Rerknimitr R and Kullavanijaya P: Pancreatic
cancer in an Asian population. Endosc Ultrasound. 4:56–62. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gall TMH, Tsakok M, Wasan H and Jiao LR:
Pancreatic cancer: Current management and treatment strategies.
Postgrad Med J. 91:601–607. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pliarchopoulou K and Pectasides D:
Pancreatic cancer: Current and future treatment strategies. Cancer
Treat Rev. 35:431–436. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Luo G, Guo M, Liu Z, Xiao Z, Jin K, Long
J, Liu L, Liu C, Xu J, Ni Q and Yu X: Blood neutrophil-lymphocyte
ratio predicts survival in patients with advanced pancreatic cancer
treated with chemotherapy. Ann Surg Oncol. 22:670–676. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Foley K, Kim V, Jaffee E and Zheng L:
Current progress in immunotherapy for pancreatic cancer. Cancer
Lett. 381:244–251. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi S, Yao W, Xu J, Long J, Liu C and Yu
X: Combinational therapy: New hope for pancreatic cancer? Cancer
Lett. 317:127–135. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Seicean A, Petrusel L and Seicean R: New
targeted therapies in pancreatic cancer. World J Gastroenterol.
21:6127–6145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rodeiro I, Magarino Y, Ocejo O, Garrido G
and Delgado R: Use of natural products in anti-cancer alternative
therapy: Risk of interactions with conventional anti-cancer drugs.
Bol. Latinoam Caribe Plant Med Aromaticas. 7:332–344. 2008.
|
|
11
|
Sozen H, Celik OI, Cetin ES, Yilmaz N,
Aksozek A, Topal Y, Cigerci IH and Beydilli H: Evaluation of the
protective effect of silibinin in rats with liver damage caused by
itraconazole. Cell Biochem Biophys. 71:1215–1223. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheung CW, Gibbons N, Johnson DW and Nicol
DL: Silibinin-a promising new treatment for cancer. Anti Cancer
Agents Med Chem. 10:186–195. 2010. View Article : Google Scholar
|
|
13
|
Gazák R, Walterová D and Kren V: New and
emerging applications in medicine. Curr Med Chem. 14:315–338. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tiwari P and Kaushala PM: Silibinin in
cancer therapy: A promising prospect. Cancer Res Front. 1:303–318.
2015. View Article : Google Scholar
|
|
15
|
Ge Y, Zhang Y, Chen Y, Li Q, Chen J, Dong
Y and Shi W: Silibinin causes apoptosis and cell cycle arrest in
some human pancreatic cancer cells. Int J Mol Sci. 12:4861–4871.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nambiar D, Prajapati V, Agarwal R and
Singh RP: In vitro and in vivo anticancer efficacy of silibinin
against human pancreatic cancer BxPC-3 and PANC-1 cells. Cancer
Lett. 334:109–117. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deng R, Jun T, Xia LP, Li DD, Zhou WJ,
Wang LL, Feng GK, Zeng YX, Gao YH and Zhu XF: ExcisaninA, a
diterpenoid compound purified from Isodon MacrocalyxinD, induces
tumor cells apoptosis and suppresses tumor growth through
inhibition of PKB/AKT kinase activity and blockade of its signal
pathway. Mol Cancer Ther. 8:873–882. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brunelle JK and Letai A: Control of
mitochondrial apoptosis by the Bcl-2 family. J Cell Sci.
122:437–441. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Conroy T, Bachet JB, Ayav A, Huguet F,
Lambert A, Caramella C, Maréchal R, Van Laethem JL and Ducreux M:
Current standards and new innovative approaches for treatment of
pancreatic cancer. Eur J Cancer. 57:10–22. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang X, Hao J, Zhu CH, Niu YY, Ding XL,
Liu C and Wu XZ: Survival benefits of western and traditional
Chinese medicine treatment for patients with pancreatic cancer.
Medicine (Baltimore). 94:e10082015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sultana A, Smith Tudur C, Cunningham D,
Starling N, Tait D, Neoptolemos JP and Ghaneh P: Systematic review,
including meta-analyses, on the management of locally advanced
pancreatic cancer using radiation/combined modality therapy. Brit J
Cancer. 96:1183–1190. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pradhan S and Girish C: Hepatoprotective
herbal drug, silymarin from experimental pharmacology to clinical
medicine. Indian J Med Res. 124:491–504. 2006.PubMed/NCBI
|
|
23
|
Magliulo E, Gagliardi B and Fiori GP:
Results of a double blind study on the effect of silymarin in the
treatment of acute viral hepatitis, carried out at two medical
centres (author's transl). Med Klin. 73:1060–1065. 1978.(In
German). PubMed/NCBI
|
|
24
|
Deep G and Agarwal R: Antimetastatic
efficacy of silibinin: Molecular mechanisms and therapeutic
potential against cancer. Cancer Metastasis Rev. 29:447–463. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng D, Wang Y, Zhang D, Liu Z, Duan C,
Jia L, Wang F, Liu Y, Liu G, Hao L and Zhang Q: In vitro antitumor
activity of silybin nanosuspension in PC-3 cells. Cancer Lett.
307:158–164. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu KJ, Zeng J, Zhu GD, Zhang LL, Zhang D,
Li L, Fan JH, Wang XY and He DL: Silibinin inhibits prostate cancer
invasion, motility and migration by suppressing vimentin and MMP-2
expression. Acta Pharmacol Sin. 30:1162–1168. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hogan FS, Krishnegowda NK, Mikhailova M
and Kahlenberg MS: Flavonoid, silibinin inhibits proliferation and
promotes cell-cycle arrest of human colon cancer. J Surg Res.
143:58–65. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Y, Li Q, Ge Y, Chen Y, Chen J, Dong
Y and Shi W: Silibinin triggers apoptosis and cell-cycle arrest of
SGC7901 cells. Phytother Res. 27:397–403. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lah JJ, Cui W and Hu KQ: Effects and
mechanisms of silibinin on human hepatoma cell lines. World J
Gastroenterol. 13:5299–5305. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu K, Zeng J, Li L, Fan J, Zhang D, Xue Y,
Zhu G, Yang L, Wang X and He D: Silibinin reverses
epithelial-to-mesenchymal transition in metastatic prostate cancer
cells by targeting transcription factors. Oncol Rep. 23:1545–1552.
2010.PubMed/NCBI
|
|
31
|
Tyagi A, Bhatia N, Condon MS, Bosland MC,
Agarwal C and Agarwal R: Antiproliferative and apoptotic effects of
silibinin in rat prostate cancer cells. Prostate. 53:211–217. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Y, Ge Y, Chen Y, Li Q, Chen J, Dong
Y and Shi W: Cellular and molecular mechanisms of silibinin induces
cell-cycle arrest and apoptosis on HeLa cells. Cell Biochem Funct.
30:243–248. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tyagi A, Agarwal C, Harrison G, Glode LM
and Agarwal R: Silibinin causes cell cycle arrest and apoptosis in
human bladder transitional cell carcinoma cells by regulating
CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages.
Carcinogenesis. 25:1711–1720. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kaur M, Velmurugan B, Tyagi A, Deep G,
Katiyar S, Agarwal C and Agarwal R: Silibinin suppresses growth and
induces apoptotic death of human colorectal carcinoma LoVo cells in
culture and tumor xenograft. Mol Cancer Ther. 8:2366–2374. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Indran IR, Tufo G, Pervaiz S and Brenner
C: Recent advances in apoptosis, mitochondria and drug resistance
in cancer cells. Biochem Biophys Acta. 1807:735–745.
2011.PubMed/NCBI
|
|
36
|
Gogvadze V, Orrenius S and Zhivotovsky B:
Mitochondria as targets for cancer chemotherapy. Semin Cancer Biol.
19:57–66. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Costantini P, Bruey JM, Castedo M,
Métivier D, Loeffler M, Susin SA, Ravagnan L, Zamzami N, Garrido C
and Kroemer G: Pre-processed caspase-9 contained in mitochondria
participates in apoptosis. Cell Death Differ. 9:82–88. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bialik S, Zalckvar E, Ber Y, Rubinstein AD
and Kimchi A: Systems biology analysis of programmed cell death.
Trends Biochem Sci. 35:556–564. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lüthi AU and Martin SJ: The CASBAH: A
searchable database of caspase substrates. Cell Death Differ.
14:641–650. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kang MH and Reynolds CP: Bcl-2 inhibitors:
Targeting mitochondrial apoptotic pathways in cancer therapy. Clin
Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ola MS, Nawaz M and Ahsan H: Role of Bcl-2
family proteins and caspases in the regulation of apoptosis. Mol
Cell Biochem. 351:41–58. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Plötz M, Gillissen B, Hossini AM, Daniel
PT and Eberle J: Disruption of the VDAC2-Bak interaction by
Bcl-x(S) mediates efficient induction of apoptosis in melanoma
cells. Cell Death Differ. 19:1928–1938. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Deng Y, Ren X, Yang L, Lin Y and Wu X: A
JNK-dependent pathway is required for TNFalpha-induced apoptosis.
Cell. 115:61–70. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Letai A, Bassik MC, Walensky LD,
Sorcinelli MD, Weiler S and Korsmeyer SJ: Distinct BH3 domains
either sensitize or activate mitochondrial apoptosis, serving as
prototype cancer therapeutics. Cancer Cell. 2:183–192. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wei Y, Sinha S and Lebive B: Dual role of
JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis
regulation. Autophagy. 4:949–951. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Duan WJ, Li QS, Xia MY, Tashiro S, Onodera
S and Ikejima T: Silibinin activated p53 and induced autophagic
death in human fibrosarcoma HT1080 cells via reactive oxygen
species-p38 and c-Jun N-terminal kinase pathways. Biol Pharm Bull.
34:47–53. 2011. View Article : Google Scholar : PubMed/NCBI
|
